Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.

PURPOSE To examine, in newly diagnosed patients with acute promyelocytic leukemia (APL), the prognostic significance of secondary cytogenetic changes and the relationship between such changes and the two major promyelocytic leukemia-retinoic acid receptor alpha (PML-RAR alpha) mRNA types. PATIENTS AND METHODS One hundred sixty-one patients with t(15;17)(q22;q11-12) enrolled onto Cancer and Leukemia Group B (CALGB) protocol 8461, a prospective study of cytogenetics in acute myeloid leukemia (AML), were studied. Eighty of these 161 patients were treated solely with chemotherapy and evaluated for response to treatment and survival. PML-RAR alpha mRNA type was determined using reverse transcriptase polymerase chain reaction (RT-PCR) in 56 patients. RESULTS The incidence of secondary cytogenetic abnormalities was 32%. Among 80 patients treated with chemotherapy, the presence of a secondary chromosome abnormality was associated with longer complete remission (CR) duration (median, 29.9 v 15.7 months; P = .03) and longer event-free survival (EFS) duration (median, 17.0 v 12.2 months; P = .03). There was no difference in overall survival (P = .28). In a separate group of 56 patients with both cytogenetic and molecular data, 32 had the type L PML-RAR alpha transcript (intron 6 PML breakpoint). Of these 32 patients, four (12.5%) had chromosome changes in addition to t(15;17), whereas 12 of 20 patients (60%) with the type 5 PML-RAR alpha transcript (intron 3 PML breakpoint) had secondary cytogenetic changes (P < .001). CONCLUSION (1) Secondary cytogenetic changes do not confer a poor prognosis in APL patients treated with anthracycline/cytarabine (Ara-C)-based chemotherapy; and (2) A highly significant relationship exists between the PML-RAR alpha 5 isoform (intron 3 PML genomic breakpoint) and secondary cytogenetic changes in APL.

[1]  T. Haferlach,et al.  Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients , 1996, British journal of haematology.

[2]  T. Haferlach,et al.  Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. , 1996, Leukemia.

[3]  R. Weichselbaum,et al.  Attenuation of G2-phase cell cycle checkpoint control is associated with increased frequencies of unrejoined chromosome breaks in human tumor cells. , 1996, Radiation research.

[4]  A. Carothers,et al.  Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. , 1996, Oncogene.

[5]  G M Lenoir,et al.  Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage , 1996, Cancer.

[6]  R. Braziel,et al.  Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. , 1995, Blood.

[7]  T. Naoe,et al.  Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). , 1995, Leukemia.

[8]  J. Bennett,et al.  Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. , 1995, Blood.

[9]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[10]  M. Andreeff,et al.  The PML gene encodes a phosphoprotein associated with the nuclear matrix. , 1995, Blood.

[11]  S. Pierce,et al.  Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype. , 1995, Leukemia.

[12]  A. Dejean,et al.  PML nuclear bodies are general targets for inflammation and cell proliferation. , 1995, Cancer research.

[13]  P. Maslak,et al.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. , 1994, Blood.

[14]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[15]  G. Lozano,et al.  PML, a growth suppressor disrupted in acute promyelocytic leukemia , 1994, Molecular and cellular biology.

[16]  S. Waxman,et al.  Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. , 1993, Blood.

[17]  D. Lydall,et al.  Cell cycle checkpoints, genetic instability and cancer. , 1993, Seminars in cancer biology.

[18]  O'Connor Pm,et al.  A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells , 1992 .

[19]  E. Dmitrovsky,et al.  Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Lo Coco,et al.  Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. , 1992, The EMBO journal.

[21]  R. Berger,et al.  Cytogenetic Studies in Acute Promyelocytic Leukemia: A Survey of Secondary Chromosomal Abnormalities , 1991, Genes, chromosomes & cancer.

[22]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[23]  C. Bloomfield,et al.  Morphologic and cytochemical characteristics of acute promyelocytic leukemia , 1989, American journal of hematology.

[24]  H. Heimpel,et al.  Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. , 1988, Blood.

[25]  A. Pardee,et al.  Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. , 1986, Cancer research.

[26]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  P. Pandolfi,et al.  Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.

[29]  A. Zelent,et al.  Occurrence of distinct PML-RAR-alpha fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. , 1992, Oncogene.

[30]  J. Kere,et al.  Chromosome 7 long arm deletion in myeloid disorders: a narrow breakpoint region in 7q22 defined by molecular mapping. , 1989, Blood.

[31]  R. Bernstein.  Cytogenetics of chronic myelogenous leukemia. , 1988, Seminars in hematology.

[32]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[33]  A. Sandberg,et al.  Prognosis of acute myeloblastic leukemia: chromosomal correlation. , 1973, Blood.

[34]  D. Cox.  Regression Models and Life-Tables , 1972 .